Literature DB >> 17352680

Azetidine-based inhibitors of dipeptidyl peptidase IV (DPP IV).

Dana Ferraris1, Sergei Belyakov, Weixing Li, Eddie Oliver, Yao-Sen Ko, David Calvin, Susan Lautar, Bert Thomas, Camilo Rojas.   

Abstract

The structure-activity relationships of azetidine-based DPP IV inhibitors will be discussed in detail in the following review. The azetidine-based DPP IV inhibitors can be divided into three main subtypes, the 2-cyanoazetidines, 3-fluoroazetidines and 2-ketoazetidines. These subtypes have been explored and structure-activity relationships have been established by several groups. Several compounds within each of these subtypes display sub micromolar potency against DPP IV. The most potent cyanoazetidines and ketoazetidines have large, hydrophobic amino acid groups bound to the azetidine nitrogen and display activities below 100 nM. DPP IV inhibition is not sensitive to stereochemistry at the 2-position as both 2-(R)- and 2-(S)-cyano and -keto azetidines display similar inhibitory potencies. While these "warhead"-based cyano- and ketoazetidines have the potential for covalent, bond-forming inhibition, they can also react to internally cyclize into inactive ketopiperazines and dihydroketopyrazine. Thus, chemical instability was also explored for compounds in these two subtypes and certain members of the cyanoazetidine series display aqueous stability comparable to the closely related cyanopyrrolidines. Select 3-fluoroazetidines also display inhibitory potencies below 1 microM without the propensity for cyclization and chemical instability associated with the other subseries.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17352680     DOI: 10.2174/156802607780090993

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  3 in total

1.  Characterization of human myotubes from type 2 diabetic and nondiabetic subjects using complementary quantitative mass spectrometric methods.

Authors:  Tine E Thingholm; Steffen Bak; Henning Beck-Nielsen; Ole N Jensen; Michael Gaster
Journal:  Mol Cell Proteomics       Date:  2011-06-22       Impact factor: 5.911

2.  Saxagliptin: A Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus.

Authors:  Jay Shubrook; Randall Colucci; Aili Guo; Frank Schwartz
Journal:  Clin Med Insights Endocrinol Diabetes       Date:  2011-01-12

3.  Stereo- and Enantioselective Addition of Organolithiums to 2-Oxazolinylazetidines as a Synthetic Route to 2-Acylazetidines.

Authors:  Pantaleo Musci; Marco Colella; Flavio Fanelli; Angela Altomare; Luisa Pisano; Claudia Carlucci; Renzo Luisi; Leonardo Degennaro
Journal:  Front Chem       Date:  2019-09-10       Impact factor: 5.221

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.